- Pollack A, Zagars GK, Starkschall G, et al. Conventional vs. conformai radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 555-64.
- Widmark A, Fransson P, Franzen L, Littbrand B, Henriksson R. Daily-diary evaluated side effects of conformai versus conventional prostatic cancer radiotherapy technique. Acta Oncol 1997; 36: 499-507.
- Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformai and conventional radiotherapy in prostate cancer: a randomised trial [see comments]. Lancet 1999; 353: 267-72.
- Sandier HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A. Three dimensional conformai radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797-801.
- Roach III M, Pickett B, Weil M, Verhey L. The 'critical volume tolerance method' for estimating the limits of dose escalation during three-dimensional conformai radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 1019-25.
- Pollack A, Zagars OK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39: 1011-8.
- Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformai treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41: 501-10.
- Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformai radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
- Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 G with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-11.
- Sandier HM, Ferez Tamayo C, Ten Haken RK, Lichter AS. Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformai therapy. Radiother Oncol 1992; 23: 53-4.
- Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformai radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect [see comments]. Int J Radiat Oncol Biol Phys 1996; 35: 251-7.
- Bergström P, Löfroth P-O, Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer--a new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 1998; 42: 305-11.
- Fransson P, Löfroth P-O, Franzen L, Henriksson R, Bergström P, Widmark A. Acute side effects after dose-escalation treatment of prostate cancer using the new urethral catheter BeamCath technique. Acta Oncol 2001; 40: 756-65.
- Henriksson R, Franzen L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol 1992; 10: 969-75.
- Landberg T, Chavaudra J, Dobbs J, et al. ICRU REPORT 50. Prescribing, recording and reporting photon beam therapy. Int Comm Radiat Units Measure 1993.
- Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformai radiation therapy affects the outcome in prostate cancer [see comments]. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
- Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformai radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
- Roach III M. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities [letter]. Radiother Oncol 1996; 40: 85-7.
- Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; (Suppl): 3845.
Free access
Daily-diary Evaluated Side Effects of Dose-escalation Radiotherapy of Prostate Cancer Using the Stereotactic Beamcath®R; Technique
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.